Neuro-Medic Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
The site conducts extensive research on immune system diseases, targeting conditions such as multiple sclerosis, myasthenia gravis and other autoimmune disorders. Trials aim to assess novel biologic agents, compare long‑term safety profiles and explore new mechanisms of disease modulation.
- Evaluation of anti‑CD20 therapies including ublituximab
- Head‑to‑head comparison of remibrutinib versus standard disease‑modifying treatments
- Pharmacokinetic and pharmacodynamic studies of biosimilar ocrelizumab
- Investigation of BTK inhibition with SAR442168 in progressive forms of MS
Research is carried out at Neuro‑Medic Sp. z o.o. in Katowice, Poland, with 21 active trials and a dedicated team of two investigators.
Musculoskeletal Diseases
Studies focus on musculoskeletal diseases that cause chronic pain and functional impairment, including low back pain, post‑surgical neuropathic pain and diabetic peripheral neuropathy. The primary goal is to identify effective analgesic strategies and improve quality of life for patients with refractory pain.
- Dose‑response characterization of VER‑01 for chronic non‑specific low back pain
- Topical capsaicin (Qutenza) versus low‑dose control for post‑surgical neuropathic pain
- Medical cannabis aerosol containing THC for diabetic peripheral neuropathic pain
- Single‑injection botulinum toxin (IPN10200) for upper‑limb spasticity after stroke or brain injury
The clinic’s multidisciplinary approach integrates pain specialists and rehabilitation experts to advance therapeutic options.
Nervous System Diseases
The research program addresses a broad spectrum of nervous system diseases, from neurodegenerative disorders such as Alzheimer’s disease to various forms of multiple sclerosis and post‑stroke spasticity. Trials are designed to test innovative drugs, evaluate disease‑modifying effects and reduce neurological disability.
- Assessment of masupirdine for agitation in Alzheimer’s disease
- Long‑term safety and efficacy of ocrelizumab in primary progressive MS
- Effectiveness of frexalimab in relapsing‑remitting multiple sclerosis
- Evaluation of serum neurofilament (sNfL) as a biomarker of disease activity
Ongoing investigations aim to slow progression, improve functional outcomes and provide new therapeutic avenues for patients with complex neurological conditions.
Physiological Processes
Research also explores fundamental physiological processes underlying disease activity, emphasizing biomarkers and advanced imaging techniques. The objective is to refine diagnostic tools, monitor treatment response and predict clinical trajectories.
- Serum neurofilament light chain (sNfL) dynamics in multiple sclerosis
- Quantitative MRI analysis of new T1 Gd‑enhancing lesions
- Whole‑brain atrophy measurement using SIENA in progressive MS
- Pharmacokinetic profiling of subcutaneous versus intravenous administration routes
These studies support personalized medicine by linking physiological markers with therapeutic outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 33 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Tg Therapeutics Inc.2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Tg Therapeutics Inc.4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Neuro-Medic Sp. z o.o.
lock Showing 1 of 25 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis. | Celltrion Inc. | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 33 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 4 | Unknown | 2019-09-19 | 2025-09-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.